Here is the dark secret of diabetes care:
Drugs like sulfonylureas and insulin that work only by lowering glucose do not consistently improve long-term outcomes in patients with diabetes.
In contrast, drugs like metformin, SGLT2 inhibitors, and GLP1 agonists that address the underlying metabolic disfunction produce long term outcomes that exceed expectations based on glucose lowering alone.
The authors of this new paper offer an intriguing explanation why:
“Insulin resistance and type 2 diabetes as allostatic responses to chronic nutrient excess” (Cell Metabolism, Jul 2026)
Paper · Cell MetabolismS1550 4131(26)00238 Xcell.comThey propose that early stage diabetes is really an attempt by the body to compensate for the harmful metabolic effects of excess calorie intake. For example, they propose that insulin resistance is really an attempt to limit glucose flux into metabolically vulnerable tissues. Instead of being a broken system, it is an active defense mechanism.
In the same way that restricting calories improves health and extends lifespan in animal models, excess consumption of calories degrades health and shortens lifespan. The authors propose that early stage diabetes is really the body attempting to mitigate the metabolic damage caused by this excess calorie intake.
They hypothesize that this explanation is fundamentally the reason why drugs that address the underlying metabolic disfunction caused by calorie excess improve long term outcomes, while drugs that only control blood sugar fail.
I would note that the same metabolic damage that occurs in diabetes as a result of calorie excess is also involved in the pathogenesis of multiple other major diseases, including the aging process itself. This may be why drugs like metformin, SGLT2 inhibitors, and GLP1 agonists seem to protect against so many other diseases, besides just diabetes. And it may be why emerging evidence in animal models and/or humans seems to suggest that these drugs may also slow biological aging.
Quoted:
“Sulfonylureas, thiazolinediones, and insulin are effective at lowering glycemia yet have not consistently translated into improved long-term outcomes. In contrast, recent interventions often produce metabolic benefits that exceed expectations based on glucose lowering alone.
These contrasting observations suggest that our understanding of T2D pathophysiology is incomplete.
We propose that, in obesity-related prediabetes and early T2D, insulin resistance, attenuated glucose-stimulated insulin secretion, modest hyperglycemia, and glucosuria represent beneficial functional changes in response to nutrient excess. These allostatic adaptive responses limit glucose flux into metabolically vulnerable tissues and reduce nutrient stress (nutri-stress).
From this perspective, T2D is not simply a failure of glucose regulation but a coordinated systemic allostatic response to chronic energy excess aimed at preserving metabolic homeostasis. Therapeutic success may depend not only on lowering glycemia but also on how interventions alter tissue-specific glucose handling and metabolic stress.”
#metforminHD #sglt2HD #glp1HD #diabetesHD #prediabetesHD #sulfonylureasHD #thiazolinedionesHD #insulinHD #agingHD


